a flurry of studies published in 2018 demonstrated that the patients’ microbiome may have something to do with this. In 2021, two studies found that transferring microbes from the fecal matter of people who did respond to the therapy to the gut of those who didn’t, could improve therapeutic benefits in the latter patients.